

10/817,328

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40
minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source
(CS) field
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for
U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and
Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human
translated claims for Chinese Applications and
Utility Models
NEWS 10 OCT 27 Free display of legal status information in CA/CAPLUS,
USPATFULL, and USPAT2 in the month of November.
NEWS 11 NOV 23 Addition of SCAN format to selected STN databases
NEWS 12 NOV 23 Annual Reload of IFI Databases

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:09:19 ON 25 NOV 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

10/817,328

	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 09:09:27 ON 25 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 NOV 2009 HIGHEST RN 1193434-24-0
DICTIONARY FILE UPDATES: 23 NOV 2009 HIGHEST RN 1193434-24-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10817328NEW2.str



```

chain nodes :
8 9 11 19 20 21 22 23 24 25 26 27 28 30 36 37 39
ring nodes :
1 2 3 4 5 6 12 13 14 15 16 17
chain bonds :
2-11 3-9 4-19 6-8 11-12 20-21 20-22 23-24 23-25 26-37 27-30 27-36
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
exact/norm bonds :
2-11 3-9 4-19 6-8 11-12 26-37 27-30 27-36
exact bonds :
20-21 20-22 23-24 23-25
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 12 :
```

10/817,328

G1:CH3,H

G2:[*1],[*2],[*3],[*4],[*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 11:CLASS 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:Atom 30:CLASS 36:CLASS
37:CLASS 39:CLASS 40:Atom

Generic attributes :

28:

Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

Element Count :

Node 28: Limited

N,N1

O,O0

S,S0

C,C5

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 09:09:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 11419 TO ITERATE

17.5% PROCESSED 2000 ITERATIONS

4 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 221975 TO 234785

PROJECTED ANSWERS: 170 TO 742

L2 4 SEA SSS SAM L1

=> d l4

L4 NOT FOUND

The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this


10/817,328

session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d 12

10/817,328

L2 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1160703-65-0 REGISTRY
ED Entered STN: 02 Jul 2009
CN 4-Pyrimidinamine, N-[4-(trifluoromethoxy)phenyl]-6-[2-[4-(trifluoromethoxy)phenyl]amino]-1H-imidazol-1-yl]- (CA INDEX NAME)
MF C21 H14 F6 N6 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/817,328

=> 3


3 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d 12

10/817,328

L2 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1160703-65-0 REGISTRY
ED Entered STN: 02 Jul 2009
CN 4-Pyrimidinamine, N-[4-(trifluoromethoxy)phenyl]-6-[2-[4-(trifluoromethoxy)phenyl]amino]-1H-imidazol-1-yl]- (CA INDEX NAME)
MF C21 H14 F6 N6 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/817,328

=> d 12 1-4

10/817,328

L2 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1160703-65-0 REGISTRY
ED Entered STN: 02 Jul 2009
CN 4-Pyrimidinamine, N-[4-(trifluoromethoxy)phenyl]-6-[2-[4-(trifluoromethoxy)phenyl]amino]-1H-imidazol-1-yl]- (CA INDEX NAME)
MF C21 H14 F6 N6 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/817,328


L2 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 957501-99-4 REGISTRY
ED Entered STN: 11 Dec 2007
CN 1H-Pyrazole-4-carboxylic acid, 5-ethyl-1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)
MF C18 H16 F3 N5 O3
SR Other Sources
Database: Specs
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/817,328

L2 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 885111-17-1 REGISTRY
ED Entered STN: 22 May 2006
CN 4-Pyrimidinamine, 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[4-
(trifluoromethyl)phenyl]- (CA INDEX NAME)
MF C19 H14 F3 N3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/817,328

L2 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 778273-48-6 REGISTRY
ED Entered STN: 10 Nov 2004
CN 4-Morpholineethanamine, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)
MF C22 H23 F3 N6 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/817,328

=> s l1 sss ful
FULL SEARCH INITIATED 09:10:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 229642 TO ITERATE

100.0% PROCESSED 229642 ITERATIONS 368 ANSWERS
SEARCH TIME: 00.00.06

L3 368 SEA SSS FUL L1

=> fila caplus
FILA IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

	SINCE FILE	TOTAL
	ENTRY	SESSION
COST IN U.S. DOLLARS	199.14	199.36
FULL ESTIMATED COST		

FILE 'CAPLUS' ENTERED AT 09:11:22 ON 25 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Nov 2009 VOL 151 ISS 22
FILE LAST UPDATED: 24 Nov 2009 (20091124/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/CAPLUS family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

=> s l3
L4 25 L3
=> d l4 1-25 bib hitstr

L4 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2009:885621 CAPLUS
 DN 151:189956
 TI Compositions and methods for treating antitumor resistant cancers using a combination of a ATP-competitive BCR-ABL inhibitor and a non-ATP BCR-ABL inhibitor
 IN Adrian, Francisco; Dierks, Christine; Gray, Nathanael S.; Warmuth, Markus
 PA IRM LLC, Bermuda
 SO PCT Int. Appl., 56pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009091476	A1	20090723	WO 2008-US87344	20081218
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2008-21008P P 20080114


OS MARPAT 151:189956

IT 778270-11-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (GNF 2; compns. and methods for treating antitumor resistant cancers using a combination of a ATP-competitive BCR-ABL inhibitor and a non-ATP BCR-ABL inhibitor)

RN 778270-11-4 CAPLUS

CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




IT 778277-15-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(GNF-5; compns. and methods for treating antitumor resistant cancers using a combination of a ATP-competitive BCR-ABL inhibitor and a non-ATP BCR-ABL inhibitor)

RN 778277-15-9 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




IT 778269-90-2 778270-03-4 778270-17-0
 778270-47-6 778270-68-1 778270-96-5
 778272-04-1 778272-35-8 778272-59-6
 778272-66-5 778273-43-1 778274-34-3
 778274-81-0 778276-83-8 778277-37-5
 778279-08-6 1173934-18-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comps. and methods for treating antitumor resistant cancers using a combination of a ATP-competitive BCR-ABL inhibitor and a non-ATP BCR-ABL inhibitor)


RN 778269-90-2 CAPLUS

CN 4-Pyrimidinamine, 6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778270-03-4 CAPLUS

CN 4-Pyrimidinamine, 6-[3-(methylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778270-17-0 CAPLUS


CN 4-Pyrimidinamine, 6-(3-aminophenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778270-47-6 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-imidazol-1-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


10/817,328




RN 778270-68-1 CAPLUS
CN Benzenesulfonamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778270-96-5 CAPLUS
CN 4-Pyrimidinamine, 6-(4-morpholinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778272-04-1 CAPLUS
CN 4-Pyrimidinamine, 6-(3-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778272-35-8 CAPLUS
CN 4-Pyrimidinamine, 6-(4-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 778272-59-6 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-


10/817,328

(CA INDEX NAME)




RN 778272-66-5 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)




RN 778273-43-1 CAPLUS

CN Ethanol, 2-[4-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-
pyridinyl]amino]- (CA INDEX NAME)




RN 778274-34-3 CAPLUS

CN Methanone, 4-morpholinyl[3-[6-[4-(trifluoromethoxy)phenyl]amino]-4-
pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778274-81-0 CAPLUS


CN Benzamide, 4-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA
INDEX NAME)



10/817,328


RN 778276-83-8 CAPLUS

CN Benamide, 4-[4-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)




RN 778277-37-5 CAPLUS

CN Benamide, N-methyl-3-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778279-08-6 CAPLUS

CN Benamide, N-[2-(4-morpholinyl)ethyl]-3-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1173934-18-3 CAPLUS

CN Benamide, N-3-pyridinyl-3-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2009 ACS ON STN
 AN 2009:702995 CAPLUS
 DN 151:49314
 TI Small molecule myristate inhibitors of bcr-abl and methods of use
 IN Gray, Nathanael S.; Zhang, Jianming; Okram, Barun; Deng, Xianming; Chang, Jaewon; Wojciechowski, Amy
 PA Dana Farber Cancer Institute, USA
 SO PCT Int. Appl., 146pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009073153	A2	20090611	WO 2008-US13219	20081128
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2007-4462P P 20071128

OS MARPAT 151:49314

IT 778276-24-7P	778276-36-1P	1160701-89-2P
1160701-92-7P	1160701-94-9P	1160703-31-0P
1160703-32-1P	1160703-33-2P	1160703-34-3P
1160703-35-4P	1160703-36-5P	1160703-37-6P
1160703-38-7P	1160703-39-8P	1160703-40-1P
1160703-41-2P	1160703-42-3P	1160703-43-4P
1160703-44-5P	1160703-45-6P	1160703-46-7P
1160703-47-8P	1160703-48-9P	1160703-49-0P
1160703-50-3P	1160703-51-4P	1160703-52-5P
1160703-53-6P	1160703-54-7P	1160703-55-8P
1160703-56-9P	1160703-57-0P	1160703-58-1P
1160703-59-2P	1160703-60-5P	1160703-61-6P
1160703-64-9P	1160703-65-0P	1160703-67-2P
1160703-69-4P	1160703-70-7P	1160703-71-8P
1160703-72-9P	1160703-73-0P	1160703-74-1P
1160703-75-2P	1160703-76-3P	1160703-77-4P
1160703-78-5P	1160703-79-6P	1160703-80-9P
1160703-81-0P	1160703-82-1P	1160703-83-2P
1160703-84-3P	1160703-85-4P	1160703-86-5P
1160703-87-6P	1160703-88-7P	1160703-89-8P
1160703-90-1P	1160703-91-2P	1160703-92-3P
1160703-93-4P	1160703-94-5P	1160703-95-6P
1160703-96-7P	1160703-97-8P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor myristate inhibitors of bcr-abl)

RN 778276-24-7 CAPLUS


CN Benzenesulfonamide, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

10/817,328




RN 778276-36-1 CAPLUS

CN 4-Pyrimidinamine, 6-[4-(4-morpholinylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160701-89-2 CAPLUS

CN Benzamide, 4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 1160701-92-7 CAPLUS


CN 4-Pyrimidinamine, 6-(1H-pyrrolo[2,3-b]pyridin-1-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160701-94-9 CAPLUS


CN 4-Pyrimidinamine, N-[4-(trifluoromethoxy)phenyl]-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)- (CA INDEX NAME)

10/817,328




RN 1160703-31-0 CAPLUS

CN Benzenesulfonamide, 4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-32-1 CAPLUS

CN Benzenesulfonamide, N-methyl-4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-33-2 CAPLUS

CN Benzenesulfonamide, N-ethyl-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-34-3 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-35-4 CAPLUS

CN 4-Pyrimidinamine, 6-[4-(methylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-36-5 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-[4-(methylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-37-6 CAPLUS

CN 4-Pyrimidinamine, 6-[4-[(1-methylethyl)sulfonyl]phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-38-7 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-[4-[(1-methylethyl)sulfonyl]phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-39-8 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-40-1 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-41-2 CAPLUS

CN 4-Pyrimidinamine, 6-[4-(1-piperidynylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-42-3 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1160703-43-4 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-[4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1160703-44-5 CAPLUS

CN Methanesulfonamide, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 1160703-45-6 CAPLUS


CN Ethanesulfonamide, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 1160703-46-7 CAPLUS


CN 1-Butanesulfonamide, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-47-8 CAPLUS

CN 2-Propanesulfonamide, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1160703-48-9 CAPLUS

CN 2-Pentanesulfonamide, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 1160703-49-0 CAPLUS


CN Benzamide, N-(2-hydroxyethyl)-4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-50-3 CAPLUS

CN Benzamide, N-(3-methoxypropyl)-4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


10/817,328




RN 1160703-51-4 CAPLUS
 CN Acetamide, N-[3-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1160703-52-5 CAPLUS
 CN Benzamide, 3-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-53-6 CAPLUS
 CN Benzoic acid, 3-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-54-7 CAPLUS
 CN 4-Pyrimidinamine, 6-[1,1'-biphenyl]-4-yl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-55-8 CAPLUS
 CN 4-Pyrimidinamine, 6-[1,1'-biphenyl]-4-yl-5-methyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-56-9 CAPLUS
 CN 4-Pyrimidinamine, 6-(8-methoxy-2-naphthalenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-57-0 CAPLUS
 CN 4-Pyrimidinamine, 6-(8-methoxy-2-naphthalenyl)-5-methyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-58-1 CAPLUS
 CN Benzeneacetonitrile, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-59-2 CAPLUS
 CN 4-Pyrimidinamine, 6-(3-nitrophenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-60-5 CAPLUS

CN Benzamide, 4-methoxy-N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1160703-61-6 CAPLUS

CN 4-Pyrimidinamine, 6-[4-(aminomethyl)phenyl]-5-methyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-64-9 CAPLUS


CN 4-Morpholineethanamine, N-[1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 1160703-65-0 CAPLUS


CN 4-Pyrimidinamine, N-[4-(trifluoromethoxy)phenyl]-6-[2-[[4-(trifluoromethoxy)phenyl]amino]-1H-imidazol-1-yl]- (CA INDEX NAME)

10/817,328




RN 1160703-67-2 CAPLUS

CN 4-Pyrimidinamine, 6-(3-amino-5-cyclopropyl-1H-pyrazol-1-yl)-N-(4-(trifluoromethoxy)phenyl)- (CA INDEX NAME)



RN 1160703-69-4 CAPLUS


CN 4-Pyrimidinamine, 6-(1H-pyrazol-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-70-7 CAPLUS

CN 4-Pyrimidinamine, 6-(1-methyl-1H-pyrazol-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


10/817,328




RN 1160703-71-8 CAPLUS
 CN 4-Pyrimidinamine, 6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-72-9 CAPLUS
 CN 4-Pyrimidinamine, 5-methyl-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-73-0 CAPLUS
 CN 4-Pyrimidinamine, 6-[1-[[4-(methylsulfonyl)phenyl]methyl]-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-74-1 CAPLUS


CN 4-Pyrimidinamine, 6-[1-(ethylsulfonyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-75-2 CAPLUS

CN 4-Pyrimidinamine, 6-[1-(4-pyridinylmethyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


10/817,328



RN 1160703-76-3 CAPLUS
CN [4,4'-Bipyrimidine]-6,6'-diamine, N6-[2-(4-morpholinyl)ethyl]-N6'-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-77-4 CAPLUS
CN 4-Pyrimidinamine, 5-methyl-6-(1-methyl-1H-pyrazol-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-78-5 CAPLUS
CN 4-Pyrimidinamine, 6-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-79-6 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-80-9 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-indol-7-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-81-0 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-indol-3-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-82-1 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-indol-6-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


10/817,328

INDEX NAME)




RN 1160703-83-2 CAPLUS

CN 2-Furancarboxaldehyde, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-84-3 CAPLUS

CN 4-Pyrimidinamine, 6-benzo[b]thien-7-yl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-85-4 CAPLUS


CN 4-Pyrimidinamine, 6-(1H-indol-7-yl)-5-methyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-86-5 CAPLUS

CN 4-Pyrimidinamine, 6-(4-dibenzofuranyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


10/817,328




RN 1160703-87-6 CAPLUS
CN 4-Pyrimidinamine, 6-[1-(phenylmethyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-88-7 CAPLUS
CN 4-Pyrimidinamine, 5-methyl-6-[1-(phenylmethyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-89-8 CAPLUS
CN [4,4'-Bipyrimidine]-6,6'-diamine, N6,N6'-bis[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-90-1 CAPLUS
CN Benzamide, N-[4-methyl-3-[[1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-1H-imidazol-2-yl]amino]phenyl]- (CA INDEX NAME)




RN 1160703-91-2 CAPLUS

CN Benzamide, N-[4-methyl-3-[[1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-1H-imidazol-2-yl]amino]phenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 1160703-92-3 CAPLUS


CN 4-Pyrimidinamine, 6-[1-(3-pyridinylmethyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-93-4 CAPLUS


CN 4-Pyrimidinamine, 6-(1H-pyrrolo[2,3-b]pyridin-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-94-5 CAPLUS

CN 2(1H)-Pyridinone, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-
(CA INDEX NAME)




RN 1160703-95-6 CAPLUS

CN 4-Pyrimidinamine, 6-[2-methyl-4-thiazolyl]-N-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)




RN 1160703-96-7 CAPLUS

CN Benzaldehyde, 2-fluoro-5-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-
(CA INDEX NAME)




RN 1160703-97-8 CAPLUS

CN 4-Pyrimidinamine, 6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)




10/817,328

IT 1160701-90-5P 1160701-91-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(antitumor myristate inhibitors of bcr-abl)
RN 1160701-90-5 CAPLUS
CN 4-Pyrimidinamine, 6-(4-chlorophenyl)-5-methyl-N-[4-
(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160701-91-6 CAPLUS
CN Benzoic acid, 4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-
pyrimidinyl]- (CA INDEX NAME)



L4 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2009:237899 CAPLUS
 DN 150:252611
 TI Methods and compositions of a hedgehog signaling antagonist and a BCR-ABL inhibitor for treating cancers
 IN Dierks, Christine; Warmuth, Markus
 PA Irm LLC, Bermuda
 SO PCT Int. Appl., 49pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009026075	A1	20090226	WO 2008-US73049	20080813
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			


PRAI US 2007-956295P P 20070816

IT 778270-11-4, GNF 2

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination of hedgehog signaling antagonist and BCR-ABL inhibitor for treating cancers)

RN 778270-11-4 CAPLUS


CN Benamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/817,328

L4 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:80325 CAPLUS
DN 150:321331
TI An intracellular conformational sensor assay for Abl T315I
AU Zhou, Vicki; Gao, Xiaoli; Han, Shulin; Brinker, Achim; Caldwell, Jeremy
S.; Gu, Xiang-Ju
CS Genomics Institute of the Novartis Research Foundation, San Diego, CA,
92121, USA
SO Analytical Biochemistry (2009), 385(2), 300-308
CODEN: ANBCA2; ISSN: 0003-2697
PB Elsevier B.V.
DT Journal
LA English
IT 778270-11-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(intracellular conformational sensor assay for Abl T315I)
RN 778270-11-4 CAPLUS
CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA
INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2009:5955 CAPLUS
 DN 150:274884
 TI Identification of a small molecule β -secretase inhibitor that binds
 without catalytic aspartate engagement
 AU Steele, Thomas G.; Hills, Ivory D.; Nomland, Ashley A.; de Leon, Pablo;
 Allison, Timothy; McGaughey, Georgia; Colussi, Dennis; Tugusheva,
 Katherine; Haugabook, Sharie J.; Espeseth, Amy S.; Zuck, Paul; Graham,
 Samuel L.; Stachel, Shawn J.
 CS Department of Medicinal Chemistry, Merck Research Laboratories, Merck and
 Co., West Point, PA, 19486, USA
 SO Bioorganic & Medicinal Chemistry Letters (2009), 19(1), 17-20
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 IT 1123311-31-8
 RL DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (small mol. β -secretase inhibitor binding without catalytic
 aspartate engagement)
 RN 1123311-31-8 CAPLUS
 CN 1,3-Benzenediamine, 4-bromo-N1-(6-phenyl-4-pyrimidinyl)- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2009 ACS ON STN

AN 2008:640658 CAPLUS

DN 149:9754

TI Preparation of 2-hydroxy-1,3-diaminopropane derivatives for the treatment of neurological or vascular disorders

IN Frederiksen, Mathias; Lueoend, Rainer Martin; McCarthy, Clive; Moebitz, Henrik; Rondeau, Jean-Michel; Roy, Bernard Lucien; Rueeger, Heinrich

PA Novartis A.-G., Switz.

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008062044	A1	20080529	WO 2007-EP62701	20071122
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2007324490	A1	20080529	AU 2007-324490	20071122
	CA 2669839	A1	20080529	CA 2007-2669839	20071122
	KR 2009091139	A	20090826	KR 2009-710477	20071122
	EP 2094645	A1	20090902	EP 2007-847275	20071122
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR			
	CN 101528670	A	20090909	CN 2007-80040090	20090427
	MX 2009005182	A	20090525	MX 2009-5182	20090514
FRAI	EP 2006-124689	A	20061123		
	WO 2007-EP62701	W	20071122		
OS	MARPAT 149:9754				
IT	1029718-95-3P, (2S,3S)-3-Amino-1-chloro-4-[4-[(6-phenylpyrimidin-4-yl)amino]phenyl]butan-2-ol		1029718-96-4P, N-[(1S,2S)-3-Chloro-2-hydroxy-1-[4-[(6-phenylpyrimidin-4-yl)amino]benzyl]propyl]acetamide		
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)		(preparation of hydroxydiaminopropane derivs. for the treatment of neurol. or vascular disorders)		
RN	1029718-95-3 CAPLUS				
CN	Benzenepropanol, β -amino- α -(chloromethyl)-4-[(6-phenyl-4-pyrimidinyl)amino]-, (α S, β S)- (CA INDEX NAME)				

Absolute stereochemistry.


10/817,328



RN 1029718-96-4 CAPLUS

CN Acetamide, N-[(1S,2S)-3-chloro-2-hydroxy-1-[[4-[(6-phenyl-4-pyrimidinyl)amino]phenyl]methyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/817,328

L4 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2009 ACS ON STN
 AN 2006:1249826 CAPLUS
 DN 146:781
 TI Methods of treating pain
 IN Wabnitz, Philipp; Schauerte, Heike; Stumm, Gabriele; Freitag, Joachim
 PA Ingenium Pharmaceuticals A.-G., Germany
 SO PCT Int. Appl., 132pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006125616	A2	20061130	WO 2006-EP4924	20060524
	WO 2006125616	A3	20070419		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	EP 1901747	A2	20080326	EP 2006-743044	20060524
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	JP 2008542219	T	20081127	JP 2008-512757	20060524
	US 20090221581	A1	20090903	US 2009-920883	20090118
PRAI	US 2005-684345P	P	20050525		
	WO 2006-EP4924	W	20060524		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 146:781
 IT 848636-35-1 848637-36-5 848637-37-6
 848637-64-9 848638-16-4 848638-17-5
 848638-99-3 848639-00-9 848639-90-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods of treating pain)
 RN 848636-35-1 CAPLUS
 CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848637-36-5 CAPLUS
 CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (CA INDEX NAME)


10/817,328




RN 848637-37-6 CAPLUS
CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848637-64-9 CAPLUS
CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (CA INDEX NAME)



RN 848638-16-4 CAPLUS
CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 848638-17-5 CAPLUS
CN 1,4-Benzenediamine, N1-[6-(4-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (CA INDEX NAME)




10/817,328


RN 848638-99-3 CAPLUS
CN 1,4-Benzenediamine, N1-[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (CA
INDEX NAME)



RN 848639-00-9 CAPLUS
CN 1,4-Benzenediamine, N1-[6-(3-aminophenyl)-5-methyl-4-pyrimidinyl]- (CA
INDEX NAME)



RN 848639-90-7 CAPLUS
CN 1,3-Benzenediamine, 4-chloro-N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA
INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2009 ACS ON STN
 AN 2006:388497 CAPLUS
 DN 144:432833
 TI Preparation of substituted nitrogen-containing heterocycles as vanilloid
 receptor ligands for treating various diseases
 IN Norman, Mark H.; Ognyanov, Vassil I.; Rzas, Robert M.
 PA Amgen Inc., USA
 SO U.S. Pat. Appl. Publ., 34 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060089360	A1	20060427	US 2005-256427	20051021
	US 7314933	B2	20080101		
	AU 2005299489	A1	20060504	AU 2005-299489	20051021
	CA 2584167	A1	20060504	CA 2005-2584167	20051021
	WO 2006047492	A2	20060504	WO 2005-US38327	20051021
	WO 2006047492	A3	20070419		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1807418	A2	20070718	EP 2005-817010	20051021
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI	US 2004-621139P	P	20041022		
	WO 2005-US38327	W	20051021		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 144:432833

IT	851984-86-6P	851984-90-2P	851985-04-1P
	851985-06-3P	852063-00-4P	885111-17-1P
	885111-18-2P	885111-19-3P	885111-20-6P
	885111-21-7P		


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted nitrogen-containing heterocycles as vanilloid receptor ligands for treating various diseases)


RN 851984-86-6 CAPLUS

CN 4-Pyrimidinamine, 6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


10/817,328




RN 851984-90-2 CAPLUS
CN 4-Pyrimidinamine, 6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA
INDEX NAME)



RN 851985-04-1 CAPLUS
CN 4-Pyrimidinamine, 6-(5-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA
INDEX NAME)




RN 851985-06-3 CAPLUS
CN 4-Pyrimidinamine, 6-(6-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA
INDEX NAME)




RN 852063-00-4 CAPLUS
CN 4-Pyrimidinamine, 6-(6-quinoxalyl)-N-[4-(trifluoromethyl)phenyl]- (CA
INDEX NAME)

10/817,328




RN 885111-17-1 CAPLUS

CN 4-Pyrimidinamine, 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 885111-18-2 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-indol-5-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 885111-19-3 CAPLUS

CN 4-Pyrimidinamine, 6-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 885111-20-6 CAPLUS


CN 4-Pyrimidinamine, 6-(2,3-dihydro-5-benzofuranyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 885111-21-7 CAPLUS

10/817,328

CN 4-Pyrimidinamine, 6-(5-isoquinoliny)-N-[4-(trifluoromethyl)phenyl]- (CA
INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:343626 CAPLUS
 DN 144:382034
 TI Besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain and other conditions requiring administration of a VR1 antagonist
 IN Cai, Dongwei; Jones, A. Brian
 PA Merck Sharp & Dohme Limited, UK; Merck & Co., Inc.
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006038041	A1	20060413	WO 2005-GB50172	20051004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-617134P P 20041008

OS MARPAT 144:382034

IT 882686-43-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain and other conditions requiring administration of VR1 antagonist)


RN 882686-43-3 CAPLUS

CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-53-0

CMF C21 H14 F4 N4



10/817,328

CM 2

CRN 98-11-3

CMF C6 H6 O3 S



IT	882685-36-1	882685-39-4	882685-44-1
	882685-46-3	882685-48-5	882685-50-9
	882685-51-0	882685-52-1	882685-53-2
	882685-54-3	882685-55-4	882685-56-5
	882685-57-6	882685-59-8	882685-70-3
	882685-72-5	882685-74-7	882685-80-5
	882685-81-6	882685-83-8	882685-84-9
	882685-90-7	882685-96-3	882686-00-2
	882686-02-4	882686-31-9	882686-32-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain and other conditions requiring administration of VR1 antagonist)


RN 882685-36-1 CAPLUS

CN 4-Pyrimidinamine, 6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851984-86-6

CMF C20 H13 F3 N4




CM 2

CRN 98-11-3

CMF C6 H6 O3 S

10/817,328




RN 882685-39-4 CAPLUS

CN 4-Pyrimidinamine, 6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851984-90-2


CMF C20 H13 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-44-1 CAPLUS

CN 4-Pyrimidinamine, 6-(5-methoxy-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 882685-43-0

CMF C21 H15 F3 N4 O




10/817,328

CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-46-3 CAPLUS

CN 4-Pyrimidinamine, 6-(5-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 882685-45-2


CMF C21 H15 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 882685-48-5 CAPLUS


CN 4-Pyrimidinamine, 6-(5-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 882685-47-4

CMF C20 H12 F4 N4


10/817,328



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-50-9 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-02-9


CMF C21 H15 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



10/817,328


RN 882685-51-0 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-03-0


CMF C21 H15 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-52-1 CAPLUS

CN 4-Pyrimidinamine, 6-(5-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-04-1

CMF C20 H13 F3 N4




CM 2

CRN 98-11-3

CMF C6 H6 O3 S

10/817,328




RN 882685-53-2 CAPLUS

CN 4-Pyrimidinamine, 6-(6-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-06-3


CMF C20 H13 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-54-3 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-07-4


CMF C21 H15 F3 N4



CM 2

10/817,328


CRN 98-11-3
CMF C6 H6 O3 S



RN 882685-55-4 CAPLUS
CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-
, benzenesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 851985-08-5
CMF C20 H12 F4 N4



CM 2

CRN 98-11-3
CMF C6 H6 O3 S




RN 882685-56-5 CAPLUS
CN 4-Pyrimidinamine, 6-(8-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-
, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-10-9
CMF C20 H12 F4 N4


10/817,328



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-57-6 CAPLUS

CN 4-Pyrimidinamine, 6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-14-3


CMF C21 H15 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 882685-59-8 CAPLUS


CN 4-Pyrimidinamine, 6-(7-isoquinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

10/817,328

CM 1

CRN 851985-18-7


CMF C20 H13 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-70-3 CAPLUS

CN 4-Pyrimidinamine, 6-(8-ethyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-40-9


CMF C22 H17 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



10/817,328


RN 882685-72-5 CAPLUS

CN 4-Pyrimidinamine, 6-(8-ethyl-7-quinolinyl)-5-methyl-N-(4-(trifluoromethyl)phenyl)-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-42-1


CMF C23 H19 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-74-7 CAPLUS

CN 4-Pyrimidinamine, N-[2-fluoro-4-(trifluoromethyl)phenyl]-5-methyl-6-(7-quinolinyl)-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-44-3

CMF C21 H14 F4 N4




CM 2

CRN 98-11-3

CMF C6 H6 O3 S

10/817,328




RN 882685-80-5 CAPLUS

CN 4-Pyrimidinamine, 6-(1,8-naphthyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-51-2


CMF C19 H12 F3 N5



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-81-6 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-52-3

CMF C21 H15 F3 N4




10/817,328

CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-83-8 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[4-(trifluoromethyl)-7-quinolinyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-54-5


CMF C21 H12 F6 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 882685-84-9 CAPLUS


CN 4-Pyrimidinamine, 5-methyl-N-[4-(trifluoromethyl)phenyl]-6-[4-(trifluoromethyl)-7-quinolinyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-55-6

CMF C22 H14 F6 N4


10/817,328



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-90-7 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(1,8-naphthyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-61-4


CMF C20 H14 F3 N5



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 882685-96-3 CAPLUS


10/817,328

CN 4-Pyrimidinamine, 5-methyl-6-(1,5-naphthyridin-3-yl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-66-9


CMF C20 H14 F3 N5



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882686-00-2 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(1-methyl-1H-benzimidazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-68-1

CMF C20 H16 F3 N5




CM 2

CRN 98-11-3

CMF C6 H6 O3 S

10/817,328




RN 882686-02-4 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-benzimidazol-6-yl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-69-2


CMF C18 H12 F3 N5



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882686-31-9 CAPLUS

CN 4-Pyrimidinamine, 6-(6-quinoxaliny)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852063-00-4

CMF C19 H12 F3 N5



10/817,328

CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882686-32-0 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(6-quinoxaliny)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852063-01-5

CMF C20 H14 F3 N5



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




IT 851985-53-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(besylate salts of six-membered amino-heterocycles as vanilloid-1
receptor antagonists for treating pain and other conditions requiring
administration of VR1 antagonist)

RN 851985-53-0 CAPLUS

CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/817,328



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:301346 CAPLUS

DN 144:350708

TI Novel pyrimidine compounds, process for their preparation, pharmaceutical compositions, and their use as antiinflammatory, cytotoxic, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases

IN Kallela, Srinivas; Padakanti, Srinivas; Kumar Swamy, Nalivela; Yeleswarapu, Koteswar Rao; Alexander, Christopher W.; Khanna, Ish Kumar; Iqbal, Javed; Pillarisetti, Sivaram; Pal, Manojit; Barange, Deepak

PA Reddy US Therapeutics, Inc., USA

SO PCT Int. Appl., 336 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006034473	A2	20060330	WO 2005-US34243	20050923
	WO 2006034473	A3	20061214		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005286592	A1	20060330	AU 2005-286592	20050923
	CA 2581454	A1	20060330	CA 2005-2581454	20050923
	US 20060084644	A1	20060420	US 2005-234257	20050923
	US 7622486	B2	20091124		
	US 20060084645	A1	20060420	US 2005-234695	20050923
	EP 1796673	A2	20070620	EP 2005-799686	20050923
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	JP 2008538544	T	20081030	JP 2007-533673	20050923
	IN 2007CN01626	A	20070831	IN 2007-CN1626	20070420
	ZA 2007003277	A	20080625	ZA 2007-3277	20070420
PRAI	US 2004-612374P	P	20040923		
	WO 2005-US34243	W	20050923		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 144:350708

IT 881194-14-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)

RN 881194-14-5 CAPLUS


CN 4-Pyrimidinamine, 6-phenyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




OSC.G	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:49982 CAPLUS
 DN 144:205343
 TI Allosteric inhibitors of Bcr-abl-dependent cell proliferation
 AU Adrian, Francisco J.; Ding, Qiang; Sim, Taebo; Velentza, Anastasia; Sloan, Christine; Liu, Yi; Zhang, Guobao; Hur, Wooyoung; Ding, Sheng; Manley, Paul; Mestan, Juergen; Fabbro, Doriano; Gray, Nathanael S.
 CS Biological Chemistry Department, Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA
 SO Nature Chemical Biology (2006), 2(2), 95-102
 CODEN: NCBABT; ISSN: 1552-4450
 PB Nature Publishing Group
 DT Journal
 LA English
 IT 778270-11-4, GNF 2 875557-38-3, GNF 3
 875557-39-4, GNF 4
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (allosteric inhibitors of Bcr-abl-dependent cell proliferation)
 RN 778270-11-4 CAPLUS
 CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 875557-38-3 CAPLUS
 CN Benzamide, N-(17-amino-3,6,9,12,15-pentaoxaheptadec-1-yl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



PAGE 1-A



PAGE 1-B



RN 875557-39-4 CAPLUS
 CN Benzamide, N-(17-amino-3,6,9,12,15-pentaoxaheptadec-1-yl)-3-[6-[methyl[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



OSC.G 45 THERE ARE 45 CAPLUS RECORDS THAT CITE THIS RECORD (45 CITINGS)
 RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:10841 CAPLUS

DN 144:108340

TI Preparation of 4,6-disubstituted pyrimidines and their use as kinase inhibitors, particularly protein kinase B/Akt inhibitors, for treating neoplasm

IN Wirschun, Wolfgang; Herdemann, Matthias; Stadlwieser, Josef; Baer, Thomas; Maier, Thomas; Beckers, Thomas; Ciossek, Thomas; Zuelch, Armin; Graedler, Ulrich

PA Altana Pharma AG, Germany

SO PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006000589	A1	20060105	WO 2005-EP53019	20050628
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005256659	A1	20060105	AU 2005-256659	20050628
	CA 2570552	A1	20060105	CA 2005-2570552	20050628
	EP 1763526	A1	20070321	EP 2005-769611	20050628
	EP 1763526	B1	20090624		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1972934	A	20070530	CN 2005-80020545	20050628
	JP 2008504251	T	20080214	JP 2007-517306	20050628
	BR 2005012547	A	20080325	BR 2005-12547	20050628
	AT 434614	T	20090715	AT 2005-769611	20050628
	ZA 2006009637	A	20080827	ZA 2006-9637	20061120
	MX 2006014747	A	20070216	MX 2006-14747	20061215
	US 20070208034	A1	20070906	US 2006-630352	20061221
	IN 2007MN00076	A	20080215	IN 2007-MN76	20070117
	KR 2007027723	A	20070309	KR 2007-701451	20070119
PRAI	EP 2004-103011	A	20040628		
	EP 2005-102355	A	20050323		
	WO 2005-EP53019	W	20050628		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 144:108340; MARPAT 144:108340

IT 872601-51-9P, N-[6-(Dibenzofuran-4-yl)pyrimidin-4-yl]benzene-1,4-diamine trifluoroacetate 872601-94-0P,
 N-[6-(Dibenzofuran-4-yl)pyrimidin-4-yl]benzene-1,3-diamine trifluoroacetate 872602-59-0P,
 N'-[6-(Dibenzofuran-4-yl)pyrimidin-4-yl]-4-methylbenzene-1,3-diamine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of disubstituted pyrimidines and their use as protein kinase B/Akt inhibitors for treating hyperproliferative

10/817,328

diseases and/or disorders responsive to the induction of apoptosis)


RN 872601-51-9 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(4-dibenzofuranyl)-4-pyrimidinyl]-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 872601-50-8

CMF C22 H16 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872601-94-0 CAPLUS

CN 1,3-Benzenediamine, N1-[6-(4-dibenzofuranyl)-4-pyrimidinyl]-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 872601-93-9

CMF C22 H16 N4 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/817,328



RN 872602-59-0 CAPLUS

CN 1,3-Benzenediamine, N3-[6-(4-dibenzofuranyl)-4-pyrimidinyl]-4-methyl- (CA
INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:696886 CAPLUS
 DN 143:194017
 TI Preparation of heteroaryl-substituted
 pyrimidinylaminophenylbenzenesulfonamides as kinase inhibitors
 IN Barsig, Johannes; Baudler, Monika; Bundschuh, Daniela; Gantner, Florian;
 Graedler, Ulrich; Heit, Isabelle; Martin, Thomas; Schaefer, Michaela;
 Schlemminger, Imre; Stadlwieser, Josef; Ulrich, Wolf-Ruediger
 PA Altana Pharma A.-G., Germany
 SO PCT Int. Appl., 115 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005070900	A1	20050804	WO 2005-EP50206	20050119
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2553513	A1	20050804	CA 2005-2553513	20050119
	EP 1709007	A1	20061011	EP 2005-701549	20050119
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
	US 20080242681	A1	20081002	US 2006-586121	20060825
PRAI	EP 2004-1310	A	20040122		
	WO 2005-EP50206	W	20050119		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:194017; MARPAT 143:194017


IT 861846-69-7P, N-[6-(4-Fluorophenyl)pyrimidin-4-yl]benzene-1,4-diamine 861851-03-8P, N-[6-(2-Methyl-2,3-dihydrobenzofuran-5-yl)pyrimidin-4-yl]benzene-1,4-diamine dihydrochloride

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heteroaryl-substituted
 pyrimidinylaminophenylbenzenesulfonamides as kinase inhibitors)

RN 861846-69-7 CAPLUS


CN 1,4-Benzenediamine, N1-[6-(4-fluorophenyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 861851-03-8 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(2,3-dihydro-2-methyl-5-benzofuran-5-yl)pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)

10/817,328



● 2 HCl

OSC.G	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:612254 CAPLUS
 DN 143:133396
 TI Preparation of heterocyclyl moiety-containing amides as BCR-ABL tyrosine
 kinase inhibitors
 IN Asaki, Tetsuo; Sugiyama, Yukiteru; Segawa, Jun
 PA Nippon Shinyaku Co., Ltd., Japan
 SO PCT Int. Appl., 168 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063709	A1	20050714	WO 2004-JP19553	20041227
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004309248	A1	20050714	AU 2004-309248	20041227
	AU 2004309248	B2	20091105		
	CA 2551529	A1	20050714	CA 2004-2551529	20041227
	EP 1702917	A1	20060920	EP 2004-807908	20041227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1898208	A	20070117	CN 2004-80039048	20041227
	BR 2004018074	A	20070417	BR 2004-18074	20041227
	CN 101456841	A	20090617	CN 2008-10186347	20041227
	MX 2006007237	A	20060818	MX 2006-7237	20060622
	IN 2006CN02337	A	20070706	IN 2006-CN2337	20060626
	KR 2006127901	A	20061213	KR 2006-714770	20060721
	KR 848067	B1	20080723		
	US 20080293940	A1	20081127	US 2008-584829	20080710
	IN 2009CN02791	A	20090821	IN 2009-CN2791	20090519
PRAI	JP 2003-431398	A	20031225		
	CN 2004-80039048	A3	20041227		
	WO 2004-JP19553	W	20041227		
	IN 2006-CN2337	A3	20060626		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS MARPAT 143:133396
 IT 859213-24-4P, 4-Methyl-3-[6-(3-pyridyl)pyrimidin-4-ylamino]aniline 859213-26-6P,
 4-Methyl-3-[6-(5-pyrimidinyl)pyrimidin-4-ylamino]aniline
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heterocyclyl moiety-containing amides as BCR-ABL tyrosine kinase inhibitors)
 RN 859213-24-4 CAPLUS
 CN 1,3-Benzenediamine, 4-methyl-N3-[6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)

10/817,328



RN 859213-26-6 CAPLUS


CN 1,3-Benzenediamine, N3-[4,5'-bipyrimidin]-6-yl-4-methyl- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:451377 CAPLUS
 DN 142:482070
 TI Preparation of (iso)quinolinyl pyridinamines, pyrimidinamines,
 pyrazinamines, pyridazinamines, and triazinamines as vanilloid-1 receptor
 antagonists for treating pain.
 IN Cai, Dongwei; Hollingworth, Gregory John; Jones, A. Brian; McIver, Edward
 Giles; Moyes, Christopher Richard; Rogers, Lauren
 PA Merck Sharp & Dohme Limited, UK; Merck & Co. Inc.
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005047280	A1	20050526	WO 2004-GB4730	20041109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050197342	A1	20050908	US 2004-984336	20041109
PRAI	GB 2003-26217	A	20031110		
	GB 2004-7748	A	20040405		
	US 2004-617134P	P	20041008		
OS	CASREACT 142:482070; MARPAT 142:482070				
IT	851984-86-6P	851984-90-2P	851984-98-0P		
	851985-02-9P	851985-03-0P	851985-04-1P		
	851985-06-3P	851985-07-4P	851985-08-5P		
	851985-10-9P	851985-12-1P	851985-14-3P		
	851985-18-7P	851985-30-3P	851985-33-6P		
	851985-36-9P	851985-53-0P	851985-75-6P		
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(claimed compound; preparation of (iso)quinolinyl pyridinamines, pyrimidinamines, pyrazinamines, pyridazinamines, and triazinamines as vanilloid-1 receptor antagonists for treating pain)				
RN	851984-86-6 CAPLUS				
CN	4-Pyrimidinamine, 6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)				



10/817,328


RN 851984-90-2 CAPLUS

CN 4-Pyrimidinamine, 6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851984-98-0 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851985-02-9 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-03-0 CAPLUS


CN 4-Pyrimidinamine, 6-(3-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851985-04-1 CAPLUS

CN 4-Pyrimidinamine, 6-(5-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


10/817,328




RN 851985-06-3 CAPLUS
CN 4-Pyrimidinamine, 6-(6-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851985-07-4 CAPLUS
CN 4-Pyrimidinamine, 6-(2-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-08-5 CAPLUS
CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851985-10-9 CAPLUS
CN 4-Pyrimidinamine, 6-(8-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



10/817,328


RN 851985-12-1 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[6-(trifluoromethyl)-7-quinolinyl]- (CA INDEX NAME)




RN 851985-14-3 CAPLUS

CN 4-Pyrimidinamine, 6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851985-18-7 CAPLUS

CN 4-Pyrimidinamine, 6-(7-isoquinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-30-3 CAPLUS


CN 4-Pyrimidinamine, 6-(8-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-33-6 CAPLUS


CN 4-Pyrimidinamine, 2-methyl-6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/817,328




RN 851985-36-9 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-53-0 CAPLUS

CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-75-6 CAPLUS


CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 851985-53-0

CMF C21 H14 F4 N4


10/817,328



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:451376 CAPLUS
 DN 142:482069
 TI Preparation of quinoxazolines and related derivatives vanilloid-1 receptor antagonists for treating pain
 IN Hollingworth, Gregory John; Jones, Brian A.; McIver, Edward Giles; Moyes, Christopher Richard; Rogers, Lauren
 PA Merck Sharp & Dohme Limited, UK
 SO PCT Int. Appl., 108 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005047279	A1	20050526	WO 2004-GB4719	20041109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004289518	A1	20050526	AU 2004-289518	20041109
	CA 2545384	A1	20050526	CA 2004-2545384	20041109
	US 20050197342	A1	20050908	US 2004-984336	20041109
	EP 1685124	A1	20060802	EP 2004-798442	20041109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007510706	T	20070426	JP 2006-538935	20041109
	CN 101035780	A	20070912	CN 2004-80039870	20041109
	IN 2006DN02615	A	20070824	IN 2006-DN2615	20060510
FRAI	GB 2003-26217	A	20031110		
	GB 2004-7748	A	20040405		
	US 2004-617134P	P	20041008		
	WO 2004-GB4719	W	20041109		
OS	CASREACT 142:482069; MARPAT 142:482069				
IT	851984-86-6P, 6-(Quinolin-8-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine			851984-90-2P, 6-(Quinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851984-98-0P, 5-Methyl-6-(quinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine			851985-02-9P, 2-Methyl-6-(quinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851985-03-0P, 6-(3-Methylquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine			851985-04-1P, 6-(Quinolin-5-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851985-06-3P, 6-(Quinolin-6-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine			851985-07-4P, 6-(2-Methylquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851985-08-5P, 6-(6-Fluoroquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine			851985-10-9P, 6-(8-Fluoroquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851985-12-1P, N-[4-(Trifluoromethylphenyl)-6-[6-(trifluoromethyl)quinolin-7-yl]pyrimidin-4-amine			851985-14-3P, 6-(8-Methylquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851985-18-7P, 6-(Isoquinolin-7-yl)-N-(4-				

trifluoromethylphenyl)pyrimidin-4-amine 851985-30-3P,
 6-(8-Fluoroquinolin-7-yl)-5-methyl-N-(4-trifluoromethylphenyl)pyrimidin-4-amine 851985-33-6P, 2-Methyl-6-(8-methylquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine 851985-36-9P,
 5-Methyl-6-(8-methylquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine 851985-53-0P, 6-(6-Fluoroquinolin-7-yl)-5-methyl-N-(4-trifluoromethylphenyl)pyrimidin-4-amine 852062-40-9P,
 6-(8-Ethylquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine 852062-42-1P, 6-(8-Ethylquinolin-7-yl)-5-methyl-N-(4-trifluoromethylphenyl)pyrimidin-4-amine 852062-44-3P,
 N-(2-Fluoro-4-trifluoromethylphenyl)-5-methyl-6-(quinolin-7-yl)pyrimidin-4-amine 852062-51-2P 852062-52-3P,
 5-Methyl-6-(quinolin-8-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine 852062-54-5P, N-(4-(Trifluoromethyl)phenyl)-6-(4-(trifluoromethyl)quinolin-7-yl)pyrimidin-4-amine 852062-55-6P,
 5-Methyl-N-(4-trifluoromethylphenyl)-6-(4-(trifluoromethyl)quinolin-7-yl)pyrimidin-4-amine 852062-61-4P 852062-66-9P
 852062-68-1P, 5-Methyl-6-(1-methyl-1H-benzimidazol-5-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine 852062-69-2P,
 6-(1H-Benzimidazol-6-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine 852063-00-4P, 6-(Quinoxalin-6-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine 852063-01-5P,
 5-Methyl-6-(quinoxalin-6-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinoxazolines and related derivs. vanilloid-1 receptor antagonists for treating pain)


RN 851984-86-6 CAPLUS

CN 4-Pyrimidinamine, 6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851984-90-2 CAPLUS


CN 4-Pyrimidinamine, 6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851984-98-0 CAPLUS


CN 4-Pyrimidinamine, 5-methyl-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/817,328




RN 851985-02-9 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 851985-03-0 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



RN 851985-04-1 CAPLUS


CN 4-Pyrimidinamine, 6-(5-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA
INDEX NAME)




RN 851985-06-3 CAPLUS

CN 4-Pyrimidinamine, 6-(6-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA
INDEX NAME)


10/817,328




RN 851985-07-4 CAPLUS
CN 4-Pyrimidinamine, 6-(2-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 851985-08-5 CAPLUS
CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



RN 851985-10-9 CAPLUS
CN 4-Pyrimidinamine, 6-(8-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 851985-12-1 CAPLUS
CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[6-(trifluoromethyl)-7-
quinolinyl]- (CA INDEX NAME)



RN 851985-14-3 CAPLUS
CN 4-Pyrimidinamine, 6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-


10/817,328

(CA INDEX NAME)




RN 851985-18-7 CAPLUS

CN 4-Pyrimidinamine, 6-(7-isoquinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851985-30-3 CAPLUS

CN 4-Pyrimidinamine, 6-(8-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-33-6 CAPLUS


CN 4-Pyrimidinamine, 2-methyl-6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-36-9 CAPLUS


CN 4-Pyrimidinamine, 5-methyl-6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/817,328




RN 851985-53-0 CAPLUS

CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 852062-40-9 CAPLUS

CN 4-Pyrimidinamine, 6-(8-ethyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 852062-42-1 CAPLUS


CN 4-Pyrimidinamine, 6-(8-ethyl-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 852062-44-3 CAPLUS


CN 4-Pyrimidinamine, N-[2-fluoro-4-(trifluoromethyl)phenyl]-5-methyl-6-(7-quinolinyl)- (CA INDEX NAME)

10/817,328




RN 852062-51-2 CAPLUS

CN 4-Pyrimidinamine, 6-(1,8-naphthyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 852062-52-3 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



RN 852062-54-5 CAPLUS


CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[4-(trifluoromethyl)-7-
quinolinyl]- (CA INDEX NAME)




RN 852062-55-6 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-N-[4-(trifluoromethyl)phenyl]-6-[4-
(trifluoromethyl)-7-quinolinyl]- (CA INDEX NAME)


10/817,328




RN 852062-61-4 CAPLUS
CN 4-Pyrimidinamine, 5-methyl-6-(1,8-naphthyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 852062-66-9 CAPLUS
CN 4-Pyrimidinamine, 5-methyl-6-(1,5-naphthyridin-3-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 852062-68-1 CAPLUS
CN 4-Pyrimidinamine, 5-methyl-6-(1-methyl-1H-benzimidazol-5-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 852062-69-2 CAPLUS
CN 4-Pyrimidinamine, 6-(1H-benzimidazol-6-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


10/817,328



RN 852063-00-4 CAPLUS
CN 4-Pyrimidinamine, 6-(6-quinoxaliny)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 852063-01-5 CAPLUS
CN 4-Pyrimidinamine, 5-methyl-6-(6-quinoxaliny)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 852062-03-4, N-(4-Trifluoromethylphenyl)-6-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-benzimidazol-5-yl]pyrimidin-4-amine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinoxazolines and related derivs. vanilloid-1 receptor antagonists for treating pain)

RN 852062-03-4 CAPLUS
CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-benzimidazol-5-yl]- (CA INDEX NAME)




IT 852062-02-3P, N-(4-Trifluoromethylphenyl)-6-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-benzimidazol-6-yl]pyrimidin-4-amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoxazolines and related derivs. vanilloid-1 receptor antagonists for treating pain)

RN 852062-02-3 CAPLUS


10/817,328

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[1-[[2-(trimethylsilyl)ethoxy)methyl]-1H-benzimidazol-6-yl]- (CA INDEX NAME)




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:436088 CAPLUS
 DN 143:133336
 TI Novel and Efficient Access to Phenylamino-pyrimidine Type Protein Kinase C
 Inhibitors Utilizing a Negishi Cross-Coupling Strategy
 AU Stanetty, Peter; Hattinger, Gregor; Schnuerch, Michael; Mihovilovic, Marko
 D.
 CS Institute of Applied Synthetic Chemistry, Vienna University of Technology,
 Vienna, A-1060, Austria
 SO Journal of Organic Chemistry (2005), 70(13), 5215-5220
 CODEN: JOCEAH; ISSN: 0022-3263
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 143:133336
 IT 858351-89-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 3-{4-[2-(3-chlorophenylamino)pyrimidin-4-yl]pyridin-2-
 ylamino}propanol and analogs via Negishi-type cross-coupling reaction
 and subsequent nucleophilic substitution reactions)
 RN 858351-89-0 CAPLUS
 CN 4-Pyrimidinamine, 6-(2-fluoro-4-pyridinyl)-N-[3-(trifluoromethyl)phenyl]-
 (CA INDEX NAME)



IT 858351-92-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 3-{4-[2-(3-chlorophenylamino)pyrimidin-4-yl]pyridin-2-
 ylamino}propanol and analogs via Negishi-type cross-coupling reaction
 and subsequent nucleophilic substitution reactions)
 RN 858351-92-5 CAPLUS
 CN 1-Propanol, 3-[[4-[6-[[3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-2-
 pyridinyl]amino]- (CA INDEX NAME)



OSC.G 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:324144 CAPLUS
 DN 142:392431
 TI Pyrimidinylarylamines and pyrimidinylaryl benzamides as protein kinase
 inhibitors and their preparation
 IN Chopiuk, Greg; Furet, Pascal; Gray, Nathanael Schiander; Imbach, Patricia;
 Liu, Yi; Schoepfer, Joseph; Steensma, Ruo
 PA IRM LLC, Bermuda
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005033086	A1	20050414	WO 2004-US32473	20040930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004278413	A1	20050414	AU 2004-278413	20040930
	AU 2004278413	B2	20080731		
	CA 2539339	A1	20050414	CA 2004-2539339	20040930
	US 20050171105	A1	20050804	US 2004-956412	20040930
	US 7189729	B2	20070313		
	EP 1670771	A1	20060621	EP 2004-789483	20040930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004014930	A	20061107	BR 2004-14930	20040930
	CN 1860106	A	20061108	CN 2004-80028450	20040930
	CN 100412066	C	20080820		
	JP 2007507531	T	20070329	JP 2006-534171	20040930
	MX 2006003557	A	20060620	MX 2006-3557	20060330
	IN 2006CN01095	A	20070817	IN 2006-CN1095	20060330
PRAI	US 2003-507592P	P	20030930		
	WO 2004-US32473	W	20040930		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:392431; MARPAT 142:392431


IT 850087-67-1P, N-[3-[12-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide
 850087-68-2P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[12-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide
 850087-75-1P, N-Cyclopropyl-3-[12-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]benzamide
 850087-76-2P, [6-[2-(3-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine 850087-77-3P,
 [6-[2-(2-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine 850087-78-4P,
 [6-[2-(4-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine 850087-79-5P,
 [6-[2-(2-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine 850087-80-8P,
 [6-[2-(3-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-

trifluoromethylphenyl)amine 850087-81-9P,
 [6-[2-(4-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-
 trifluoromethylphenyl)amine 850087-82-0P,
 [6-(2-o-Tolylaminophenyl)pyrimidin-4-yl](4-trifluoromethylphenyl)amine
 850087-83-1P, [6-(2-m-Tolylaminophenyl)pyrimidin-4-yl](4-
 trifluoromethylphenyl)amine 850087-84-2P,
 [6-(2-p-Tolylaminophenyl)pyrimidin-4-yl](4-trifluoromethylphenyl)amine
 850087-85-3P, 3-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-
 yl]phenyl]amino]benzaldehyde 850087-86-4P,
 4-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-
 yl]phenyl]amino]benzaldehyde 850087-87-5P,
 (4-Trifluoromethylphenyl)[6-[2-(2-
 trifluoromethylphenylamino)phenyl]pyrimidin-4-yl]amine
 850087-88-6P, (4-Trifluoromethylphenyl)[6-[2-(4-
 trifluoromethylphenylamino)phenyl]pyrimidin-4-yl]amine
 850087-89-7P, N,N-Dimethyl-N'-[2-[6-(4-
 trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]benzene-1,4-diamine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of pyrimidine-containing arylamines and aryl
 benzamides as protein kinase inhibitors)

RN 850087-67-1 CAPLUS


CN Benzamide, N-[3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-
 pyrimidinyl]phenyl]amino]phenyl]- (CA INDEX NAME)



RN 850087-68-2 CAPLUS

CN Benzamide, 4-[[4-methyl-1-piperazinyl)methyl]-N-[3-[[2-[6-[[4-
 (trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (CA
 INDEX NAME)


PAGE 1-A



Me


RN 850087-75-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (CA INDEX NAME)




RN 850087-76-2 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(3-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 850087-77-3 CAPLUS


CN 4-Pyrimidinamine, 6-[2-[(2-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



10/817,328


RN 850087-78-4 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(4-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 850087-79-5 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2-chlorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 850087-80-8 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(3-chlorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 850087-81-9 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(4-chlorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


10/817,328

(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 850087-82-0 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 850087-83-1 CAPLUS


CN 4-Pyrimidinamine, 6-[2-[(3-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 850087-84-2 CAPLUS


CN 4-Pyrimidinamine, 6-[2-[(4-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/817,328




RN 850087-85-3 CAPLUS

CN Benzaldehyde, 3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (CA INDEX NAME)



RN 850087-86-4 CAPLUS


CN Benzaldehyde, 4-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (CA INDEX NAME)



RN 850087-87-5 CAPLUS


CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[2-[[2-(trifluoromethyl)phenyl]amino]phenyl]- (CA INDEX NAME)

10/817,328




RN 850087-88-6 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[2-[[4-(trifluoromethyl)phenyl]amino]phenyl]- (CA INDEX NAME)



RN 850087-89-7 CAPLUS

CN 1,4-Benzenediamine, N1,N1-dimethyl-N4-[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/817,328


ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:260034 CAPLUS
 DN 142:336376
 TI Preparation of pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
 IN Choidas, Axel; Backes, Alexander; Cotten, Matt; Engkvist, Ola; Felber, Beatrice; Freisleben, Achim; Godl, Klaus; Greff, Zoltan; Habenberger, Peter; Hafenbradl, Doris; Hartung, Christian; Herget, Thomas; Hoppe, Edmund; Klebl, Bert; Missio, Andrea; Mueller, Gerhard; Schwab, Wilfried; Zech, Birgit; Bravo, Jose; Harris, John; Le, Joelle; Macritchie, Jackie; Savic, Vladimir; Sherborne, Brad; Simpson, Don; Simpson, Don
 PA Axxima Pharmaceuticals AG, Germany
 SO PCT Int. Appl., 211 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026129	A1	20050324	WO 2004-EP10353	20040915
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LG, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1678147	A1	20060712	EP 2004-786953	20040915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 20070191344	A1	20070816	US 2006-572043	20061212
PRAI	EP 2003-20888	A	20030915		
	US 2003-504527P	P	20030922		
	EP 2004-10308	A	20040430		
	US 2004-569806P	P	20040512		
	WO 2004-EP10353	W	20040915		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS CASREACT 142:336376; MARPAT 142:336376
 IT 848636-35-1P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]benzene-1,4-diamine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)
 RN 848636-35-1 CAPLUS
 CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)



IT 848637-36-5P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-2-methylbenzene-1,4-diamine 848637-37-6P,
 N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]benzene-1,3-diamine
 848637-64-9P, N-[6-(2-Methoxyphenyl)-5-methylpyrimidin-4-yl]benzene-1,4-diamine 848638-16-4P,
 N-[6-(2-Methoxyphenyl)-2-methylpyrimidin-4-yl]benzene-1,4-diamine
 848638-17-5P, N-[6-(4-Methoxyphenyl)-2-methylpyrimidin-4-yl]benzene-1,4-diamine 848638-99-3P,
 N-[6-(4-Methoxyphenyl)-5-methylpyrimidin-4-yl]benzene-1,4-amine
 848639-00-9P, N-[6-(3-Aminophenyl)-5-methylpyrimidin-4-yl]benzene-1,4-amine 848639-90-7P,
 4-Chloro-N-[6-(2-methoxyphenyl)pyrimidin-4-yl]benzene-1,3-diamine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)
 RN 848637-36-5 CAPLUS
 CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (CA INDEX NAME)




RN 848637-37-6 CAPLUS
 CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848637-64-9 CAPLUS
 CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (CA INDEX NAME)


10/817,328




RN 848638-16-4 CAPLUS
CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (CA
INDEX NAME)




RN 848638-17-5 CAPLUS
CN 1,4-Benzenediamine, N1-[6-(4-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (CA
INDEX NAME)



RN 848638-99-3 CAPLUS
CN 1,4-Benzenediamine, N1-[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (CA
INDEX NAME)




RN 848639-00-9 CAPLUS
CN 1,4-Benzenediamine, N1-[6-(3-aminophenyl)-5-methyl-4-pyrimidinyl]- (CA
INDEX NAME)



10/817,328

RN 848639-90-7 CAPLUS

CN 1,3-Benzenediamine, 4-chloro-N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)



IT 848640-02-8, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-4-methylbenzene-1,3-diamine 848640-03-9,


[3-[6-(3-Amino-4-methylphenylamino)pyrimidin-4-yl]phenyl]carbamic acid 9H-fluoren-9-ylmethyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)

RN 848640-02-8 CAPLUS


CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)



RN 848640-03-9 CAPLUS

CN Carbamic acid, [3-[6-[(3-amino-4-methylphenyl)amino]-4-pyrimidinyl]phenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

10/817,328



OSC.G	9	THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:99484 CAPLUS
 DN 142:198089
 TI Preparation of azinyl aryl amines as vanilloid receptor ligands.
 IN Blum, Charles A.; Briellmann, Harry; Hodgetts, Kevin J.
 PA Neurogen Corporation, USA
 SO PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005009977	A1	20050203	WO 2004-US22820	20040715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259712	A1	20050203	AU 2004-259712	20040715
CA 2531490	A1	20050203	CA 2004-2531490	20040715
EP 1651619	A1	20060503	EP 2004-778364	20040715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1823048	A	20060823	CN 2004-80020429	20040715
JP 2007523875	T	20070823	JP 2006-520349	20040715
IN 2005DN05450	A	20070817	IN 2005-DN5450	20051125
US 20060229308	A1	20061012	US 2006-564583	20060406
PRAI US 2003-487405P	P	20030715		
WO 2004-US22820	W	20040715		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:198089; MARPAT 142:198089


IT 837382-73-7P 837382-95-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azinyl aryl amines as vanilloid receptor ligands)

RN 837382-73-7 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-2,5-dimethyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 837382-95-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-bromo-4-(trifluoromethyl)phenyl]-6-(3-

10/817,328

methoxyphenyl)- (CA INDEX NAME)



OSC.G	4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:878265 CAPLUS
 DN 141:366255
 TI Preparation of substituted pyrimidinamines and triazinamines as protein
 kinase inhibitors
 IN Ding, Qiang; Sim, Tae-Bo; Zhang, Guobao; Adrian, Francisco; Gray,
 Nathanael S.; Schultz, Peter G.
 PA IRM LLC, Bermuda
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089286	A2	20041021	WO 2004-US10083	20040402
	WO 2004089286	A3	20050421		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 20050014753	A1	20050120	US 2004-817328	20040401
	AU 2004227943	A1	20041021	AU 2004-227943	20040402
	AU 2004227943	B2	20080904		
	CA 2521184	A1	20041021	CA 2004-2521184	20040402
	EP 1613595	A2	20060111	EP 2004-758738	20040402
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	BR 2004009173	A	20060411	BR 2004-9173	20040402
	CN 1798734	A	20060705	CN 2004-80015433	20040402
	JP 2006522143	T	20060928	JP 2006-509594	20040402
	MX 2005010711	A	20051215	MX 2005-10711	20051004
	IN 2005CN02515	A	20070831	IN 2005-CN2515	20051004
PRAI	US 2003-460838P	P	20030404		
	US 2004-817328	A	20040401		
	WO 2004-US10083	W	20040402		
OS	MARPAT 141:366255				
IT	714962-06-8P	778269-75-3P	778269-83-3P		
	778269-90-2P	778269-96-8P	778270-03-4P		
	778270-11-4P	778270-17-0P	778270-47-6P		
	778270-56-7P	778270-68-1P	778270-88-5P		
	778270-96-5P	778271-56-0P	778271-64-0P		
	778271-72-0P	778271-79-7P	778271-87-7P		
	778271-96-8P	778272-04-1P	778272-13-2P		
	778272-18-7P	778272-26-7P	778272-35-8P		
	778272-44-9P	778272-59-6P	778272-66-5P		
	778272-73-4P	778272-97-2P	778273-04-4P		
	778273-14-6P	778273-19-1P	778273-25-9P		
	778273-32-8P	778273-36-2P	778273-43-1P		
	778273-48-6P	778273-56-6P	778273-63-5P		
	778273-70-4P	778273-75-9P	778273-82-8P		
	778273-90-8P	778274-04-7P	778274-14-9P		
	778274-20-7P	778274-28-5P	778274-34-3P		


778274-38-7P	778274-42-3P	778274-49-0P
778274-58-1P	778274-65-0P	778274-74-1P
778274-81-0P	778274-89-8P	778274-97-8P
778275-02-8P	778275-08-4P	778275-15-3P
778275-21-1P	778275-31-3P	778275-36-8P
778275-45-9P	778275-51-7P	778275-58-4P
778275-64-2P	778275-72-2P	778275-78-8P
778275-86-8P	778275-92-6P	778276-06-5P
778276-12-3P	778276-24-7P	778276-30-5P
778276-36-1P	778276-42-9P	778276-48-5P
778276-64-5P	778276-70-3P	778276-77-0P
778276-83-8P	778276-89-4P	778276-94-1P
778276-99-6P	778277-07-9P	778277-15-9P
778277-22-8P	778277-24-0P	778277-31-9P
778277-37-5P	778277-44-4P	778277-49-9P
778277-54-6P	778277-62-6P	778277-67-1P
778277-74-0P	778279-08-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors for treating tumors)


RN 714962-06-8 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 778269-75-3 CAPLUS

CN Benzamide, N,N-dimethyl-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778269-83-3 CAPLUS


CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778269-90-2 CAPLUS

10/817,328


CN 4-Pyrimidinamine, 6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778269-96-8 CAPLUS
CN 4-Pyrimidinamine, 6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778270-03-4 CAPLUS
CN 4-Pyrimidinamine, 6-[3-(methylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778270-11-4 CAPLUS
CN Benzamide, 3-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778270-17-0 CAPLUS
CN 4-Pyrimidinamine, 6-(3-aminophenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778270-47-6 CAPLUS


10/817,328

CN 4-Pyrimidinamine, 6-(1H-imidazol-1-yl)-N-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)




RN 778270-56-7 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778270-68-1 CAPLUS

CN Benzenesulfonamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778270-88-5 CAPLUS


CN Benzamide, N-(2-hydroxyethyl)-4-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)



RN 778270-96-5 CAPLUS


CN 4-Pyrimidinamine, 6-(4-morpholinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 778271-56-0 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778271-64-0 CAPLUS

CN 4-Pyrimidinamine, 6-(1,3-benzodioxol-5-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778271-72-0 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778271-79-7 CAPLUS

CN Benzenemethanol, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778271-87-7 CAPLUS

CN 4-Pyrimidinamine, 6-(1-piperazinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA


10/817,328

INDEX NAME)




RN 778271-96-8 CAPLUS

CN 4-Pyrimidinamine, 6-(1-oxido-4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)




RN 778272-04-1 CAPLUS

CN 4-Pyrimidinamine, 6-(3-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA
INDEX NAME)




RN 778272-13-2 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methyl-1H-imidazol-1-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778272-18-7 CAPLUS


CN 4-Pyrimidinamine, 6-(5-methyl-1H-pyrazol-1-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



10/817,328


RN 778272-26-7 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-benzimidazol-1-yl)-N-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)




RN 778272-35-8 CAPLUS

CN 4-Pyrimidinamine, 6-(4-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (CA
INDEX NAME)




RN 778272-44-9 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)




RN 778272-59-6 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)



RN 778272-66-5 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)




RN 778272-73-4 CAPLUS

CN 4-Pyrimidinamine, 6-(6-chloro-3-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-


10/817,328

(CA INDEX NAME)




RN 778272-97-2 CAPLUS

CN Ethanone, 1-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-1-piperazinyl]- (CA INDEX NAME)




RN 778273-04-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-pyrazinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778273-14-6 CAPLUS

CN 4-Piperidinone, 1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778273-19-1 CAPLUS


CN 4-Piperidinone, 1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-, O-methylloxime (CA INDEX NAME)



RN 778273-25-9 CAPLUS


CN 4-Pyrimidinamine, 6-(2-chloro-4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 778273-32-8 CAPLUS

CN 1,3-Propanediamine, N1,N1-dimethyl-N3-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)




RN 778273-36-2 CAPLUS

CN 1,3-Propanediamine, N1-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)




RN 778273-43-1 CAPLUS

CN Ethanol, 2-[[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]amino]- (CA INDEX NAME)



RN 778273-48-6 CAPLUS


CN 4-Morpholineethanamine, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)



RN 778273-56-6 CAPLUS


CN 4-Pyrimidinamine, 6-[2-[[4-(pyridinylmethyl)amino]-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 778273-63-5 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[2-(dimethylamino)ethoxy]-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778273-70-4 CAPLUS

CN 4-Pyrimidinamine, 6-[2-(4-morpholinyl)-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778273-75-9 CAPLUS

CN 4-Pyrimidinamine, 6-[2-(1-piperazinyl)-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778273-82-8 CAPLUS


CN Ethanone, 1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778273-90-8 CAPLUS


CN Acetamide, N-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)

10/817,328




RN 778274-04-7 CAPLUS

CN Benzamide, N-(1-methylethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778274-14-9 CAPLUS

CN Benzamide, N-4-morpholinyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778274-20-7 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778274-28-5 CAPLUS


CN Benzamide, N-(2-furanylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778274-34-3 CAPLUS


CN Methanone, 4-morpholinyl[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)

10/817,328



RN 778274-38-7 CAPLUS


CN Methanone, (4-ethyl-1-piperazinyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778274-42-3 CAPLUS


CN Methanone, [(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 778274-49-0 CAPLUS

CN Benzamide, N-[(tetrahydro-2-furanyl)methyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778274-58-1 CAPLUS


CN Benzamide, N-(3-pyridinylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778274-65-0 CAPLUS


CN 3-Piperidinecarboxamide, N,N-diethyl-1-[3-[6-[[4-

(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (CA INDEX NAME)




RN 778274-74-1 CAPLUS

CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778274-81-0 CAPLUS


CN Benzamide, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778274-89-8 CAPLUS

CN Methanone, [(2R)-2-(hydroxymethyl)-1-pyrrolidinyl][3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 778274-97-8 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


10/817,328



RN 778275-02-8 CAPLUS
 CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778275-08-4 CAPLUS
 CN Benzamide, N-[3-(aminocarbonyl)phenyl]-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778275-15-3 CAPLUS
 CN Methanone, [(2S)-2-(hydroxymethyl)-1-pyrrolidinyl] 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 778275-21-1 CAPLUS
 CN Methanone, [(2R)-2-(hydroxymethyl)-1-pyrrolidinyl] 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

10/817,328




RN 778275-31-3 CAPLUS

CN Methanone, 4-morpholinyl[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 778275-36-8 CAPLUS

CN Benzamide, N-[4-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778275-45-9 CAPLUS


CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778275-51-7 CAPLUS


CN 3-Piperidinecarboxamide, 1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

10/817,328




RN 778275-58-4 CAPLUS

CN Benzamide, 2-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778275-64-2 CAPLUS

CN Methanone, [3-amino-5-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 778275-72-2 CAPLUS

CN 4-Pyrimidinamine, 6-(2-aminophenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778275-78-8 CAPLUS

CN Benzamide, 4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778275-86-8 CAPLUS

CN Methanone, [4-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 778275-92-6 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-4-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778276-06-5 CAPLUS


CN Methanone, [3-amino-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 778276-12-3 CAPLUS

CN Benzamide, 3-amino-N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


10/817,328




RN 778276-24-7 CAPLUS
CN Benzenesulfonamide, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778276-30-5 CAPLUS
CN 4-Pyrimidinamine, 6-[3-(4-morpholinylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778276-36-1 CAPLUS
CN 4-Pyrimidinamine, 6-[4-(4-morpholinylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778276-42-9 CAPLUS
CN Benamide, N-(2,6-dichlorophenyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



10/817,328


RN 778276-48-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (CA INDEX NAME)




RN 778276-64-5 CAPLUS

CN Benzamide, 3-[4-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)




RN 778276-70-3 CAPLUS

CN 4-Pyrimidinamine, 6-[2-(2-aminophenyl)-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778276-77-0 CAPLUS


CN Benzamide, 2-[4-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)



RN 778276-83-8 CAPLUS


CN Benzamide, 4-[4-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)

10/817,328




RN 778276-89-4 CAPLUS

CN Benzamide, 3-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778276-94-1 CAPLUS

CN Benzamide, 4-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778276-99-6 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-07-9 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)




RN 778277-15-9 CAPLUS

CN Benamide, N-(2-hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-22-8 CAPLUS

CN Benamide, N-(4-pyridinylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-24-0 CAPLUS

CN Benamide, N-[3-(1H-imidazol-1-yl)propyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-31-9 CAPLUS

CN Methanone, [4-(2-hydroxyethyl)-1-piperazinyl][3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778277-37-5 CAPLUS


CN Benamide, N-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



10/817,328


RN 778277-44-4 CAPLUS

CN 1-Naphthalenecarboxaldehyde, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-49-9 CAPLUS

CN 2-Thiophenecarboxaldehyde, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-54-6 CAPLUS

CN Benzamide, 3-amino-N-methyl-5-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778277-62-6 CAPLUS


CN Benzamide, 2-fluoro-N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



10/817,328


RN 778277-67-1 CAPLUS

CN Benzamide, 2-cyano-N-methyl-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-74-0 CAPLUS

CN 4-Pyrimidinamine, 6-(5-quinolinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778279-08-6 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




IT 778278-85-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors for treating tumors)

RN 778278-85-6 CAPLUS

CN Benzoic acid, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:857162 CAPLUS

DN 141:350185

TI Preparation of pyrimidine derivatives with lysophosphatidic acid
acyltransferase β (LPAAT- β) inhibitory activityIN Bhatt, Rama; Gong, Baoqing; Hong, Feng; Jenkins, Scott A.; Klein, J.
Peter; Kohm, Cory T.; Tulinsky, John

PA Cell Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 80 pp., which
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040204386	A1	20041014	US 2003-671070	20030924
	US 7419984	B2	20080902		
	US 20090099183	A1	20090416	US 2008-194192	20080819
PRAI	US 2002-419694P	P	20021017		
	US 2003-460776P	P	20030404		
	US 2003-671070	A1	20030924		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 141:350185; MARPAT 141:350185


IT 774607-65-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrimidine derivs. with lysophosphatidic acid
acyltransferase β (LPAAT- β) inhibitory activity)

RN 774607-65-7 CAPLUS


CN 4-Pyrimidinamine, 6-[5-bromo-2-(methoxymethyl)phenyl]-N-[4-
(trifluoromethyl)phenyl]- (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 23 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:550744 CAPLUS
 DN 141:89118
 TI Preparation of biaryl derivatives having differential tumor cytotoxicity
 IN Chyba, Jason; Deveraux, Quinn; Hampton, Garret; King, Fred
 PA IRM Lic, Bermuda
 SO U.S. Pat. Appl. Publ., 11 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040132786	A1	20040708	US 2003-739667	20031218
	US 7125997	B2	20061024		
	WO 2004058713	A1	20040715	WO 2003-US40686	20031218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003299750	A1	20040722	AU 2003-299750	20031218
PRAI	US 2002-435853P	P	20021220		
	US 2003-491132P	P	20030729		
	WO 2003-US40686	W	20031218		
OS	MARPAT 141:89118				
IT	714962-05-7P, 3-[6-[(4-Trifluoromethoxyphenyl)amino]pyrimidin-4-yl]benzoic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of biaryl derivs. having differential tumor cytotoxicity as antitumor agents)				
RN	714962-05-7 CAPLUS				
CN	Benzoic acid, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)				




IT 714962-03-5P, 3-[6-[(4-Trifluoromethoxyphenyl)amino]pyrimidin-4-yl]-N-(2-trifluoromethylbenzyl)benzamide 714962-06-8P, 4-Methoxy-N-[3-[6-[(4-trifluoromethoxyphenyl)amino]pyrimidin-4-yl]phenyl]benzenesulfonamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of biaryl derivs. having differential tumor cytotoxicity as antitumor agents)
 RN 714962-03-5 CAPLUS
 CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

10/817,328



RN 714962-06-8 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1996:743723 CAPLUS

DN 126:18874

OREF 126:3921a,3924a

TI Preparation of benzimidazoles as modulators of the GABAA receptor complex

IN Teuber, Lene; Waetjen, Frank; Fukuda, Yoshimasa; Ushiroda, Osamu; Sasaki, Toshiro

PA Neurosearch A/S, Den.; Meiji Seika Kaisha, Ltd.

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9633194	A1	19961024	WO 1996-EP1606	19960417
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2218493	A1	19961024	CA 1996-2218493	19960417
CA 2218493	C	20050222		
AU 9656891	A	19961107	AU 1996-56891	19960417
AU 695957	B2	19980827		
EP 821684	A1	19980204	EP 1996-914932	19960417
EP 821684	B1	20011205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI				
CN 1182427	A	19980520	CN 1996-193419	19960417
CN 1072669	C	20011010		
JP 11501320	T	19990202	JP 1996-531464	19960417
JP 3342874	B2	20021111		
HU 9801692	A2	19990329	HU 1998-1692	19960417
HU 9801692	A3	20011128		
RU 2135493	C1	19990827	RU 1997-119173	19960417
BR 9608048	A	19991130	BR 1996-8048	19960417
CZ 287545	B6	20001213	CZ 1997-3292	19960417
AT 210132	T	20011215	AT 1996-914932	19960417
EP 1164134	A1	20011219	EP 2001-112476	19960417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
SK 282425	B6	20020107	SK 1997-1399	19960417
PL 183853	B1	20020731	PL 1996-322892	19960417
EE 4310	B1	20040615	EE 1997-283	19960417
CA 2217601	A1	19961024	CA 1996-2217601	19960419
CA 2217601	C	20020416		
CN 1182426	A	19980520	CN 1996-193420	19960419
AT 344257	T	20061115	AT 1996-912025	19960419
NO 9704844	A	19971216	NO 1997-4844	19971020
NO 314504	B1	20030331		
US 5922724	A	19990713	US 1998-945023	19980205
HK 1015674	A1	20021011	HK 1998-111156	19981009
PRAI DK 1995-460	A	19950421		
EP 1996-914932	A3	19960417		
WO 1996-EP1606	W	19960417		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 126:18874
IT 184097-98-1P


10/817,328

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of benzimidazoles as modulators of the GABAA receptor complex)

RN 184097-98-1 CAPLUS

CN 1,2-Benzenediamine, 4-(3-furanyl)-N1-[6-(1H-imidazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1986:478951 CAPLUS

DN 105:78951

OREF 105:12817a,12820a

TI Pyrimidine derivatives and their use

IN Takaya, Takao; Murata, Masayoshi; Ito, Kiyotaka

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Eur. Pat. Appl., 87 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 168262	A2	19860115	EP 1985-305004	19850712
	EP 168262	A3	19870513		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4725600	A	19880216	US 1985-751867	19850705
	JP 61044872	A	19860304	JP 1985-154545	19850712
PRAI	GB 1984-17852	A	19840713		
	GB 1984-23667	A	19840919		
	GB 1984-30456	A	19841203		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS MARPAT 105:78951

IT 103555-19-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as cardiovascular agent and anticoagulant)

RN 103555-19-7 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(3,4-dimethoxyphenyl)-2-methyl-4-pyrimidinyl]-
(CA INDEX NAME)

OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)

10/817,328

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

98.25

297.61

STN INTERNATIONAL LOGOFF AT 09:12:31 ON 25 NOV 2009